Ductal carcinoma in situ: risk factors and impact of screening.
BACKGROUND
The National Institutes of Health Office of Medical Applications of Research commissioned a structured literature review on the incidence of ductal carcinoma in situ (DCIS) as a background paper for the State of the Science Conference on Diagnosis and Management of DCIS.


METHODS
Published studies were abstracted from MEDLINE and other sources. We include articles published through January 31, 2009; 92 publications were abstracted.


RESULTS
DCIS incidence rose from 1.87 per 100,000 in 1973-1975 to 32.5 per 100,000 in 2005. Increases in incidence were greatest in tumors without comedo necrosis. Incidence increased in all ages but more in women older than 50 years. Increased use of mammography explains some but not all of the increased incidence. Risk factors for incident DCIS include older age and positive family history. Whereas tamoxifen prevents both invasive breast cancer and DCIS, raloxifene is associated with decreased invasive breast cancer but not decreased DCIS.


CONCLUSIONS
Scientific questions deserving further investigation include the relationship between mammography use and DCIS incidence and the role of chemoprevention for reducing the incidence of DCIS and invasive breast cancer.
Division of Health Policy and Management, School of Public Health, University of Minnesota, A365 Mayo (MMC 729), 420 Delaware St SE, Minneapolis, MN 55455, USA. virni001@umn.edu
Beth A
BA
Virnig
Shi-Yi
SY
Wang
Tatyana
T
Shamilyan
Robert L
RL
Kane
Todd M
TM
Tuttle
D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000453:epidemiology* / Q000517:prevention & control; D018270:Carcinoma, Ductal, Breast / Q000453:epidemiology / Q000517:prevention & control; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000000981:diagnostic imaging / Q000453:epidemiology* / Q000517:prevention & control; D018890:Chemoprevention / Q000706:statistics & numerical data; D005260:Female; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D008327:Mammography; D008403:Mass Screening; D008875:Middle Aged; D015337:Multicenter Studies as Topic / Q000706:statistics & numerical data; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use; D055815:Young Adult
D013629:Tamoxifen; D020849:Raloxifene Hydrochloride